| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSG |
| Uniprot No | P08311 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-244aa |
| 氨基酸序列 | IIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVLTAAHCWGSNINVTLGAHNIQRRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRRNRNVNPVALPRAQEGLRPGTLCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYDPRRQICVGDRRERKAAFKGDSGGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRTTMRS |
| 预测分子量 | 32.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTSG(Cathepsin G)重组蛋白的模拟参考文献示例(非真实文献，仅作格式参考)：
---
1. **标题**：Recombinant Human Cathepsin G: Expression, Purification, and Functional Characterization
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统高效表达并纯化重组人CTSG蛋白，验证其酶活性及在体外炎症反应中对细胞因子激活的作用。
2. **标题**：Structural Insights into CTSG Substrate Specificity via Recombinant Protein Mutagenesis
**作者**：Zhang L, et al.
**摘要**：通过定点突变重组CTSG蛋白，解析其底物结合域的关键氨基酸残基，揭示其参与病原体降解的分子机制。
3. **标题**：Role of Recombinant CTSG in Neutrophil Extracellular Trap (NET) Formation
**作者**：Tanaka K, et al.
**摘要**：利用重组CTSG蛋白研究其在NETosis中的作用，发现其通过切割组蛋白促进中性粒细胞胞外陷阱的释放。
4. **标题**：CTSG Recombinant Protein as a Therapeutic Target in Chronic Inflammation
**作者**：Müller R, et al.
**摘要**：评估重组CTSG抑制剂在小鼠关节炎模型中的疗效，证明其通过调节蛋白酶活性减轻组织损伤。
---
**注意**：以上文献为模拟内容，实际文献需通过PubMed、Web of Science或Google Scholar检索关键词(如"recombinant Cathepsin G"或"CTSG protein expression")获取。
**Background of CTSG Recombinant Protein**
Cathepsin G (CTSG) is a serine protease primarily expressed in neutrophil granulocytes, playing a critical role in innate immunity and inflammatory responses. It is stored in azurophilic granules and released during neutrophil activation, contributing to pathogen clearance, tissue remodeling, and modulation of immune signaling. CTSG exhibits both proteolytic and antimicrobial activities, targeting substrates such as extracellular matrix proteins, cytokines, and microbial pathogens. Its dysregulation has been linked to chronic inflammation, autoimmune diseases, and cancer progression.
Recombinant CTSG protein is produced using genetic engineering techniques, often in *E. coli* or mammalian expression systems, to ensure high purity and bioactivity. The recombinant form allows researchers to study CTSG's mechanisms without interference from other neutrophil-derived factors. Key applications include investigating its role in inflammatory diseases (e.g., rheumatoid arthritis, cystic fibrosis), infection defense, and tissue damage pathways. Additionally, CTSG is explored as a therapeutic target; inhibitors may mitigate inflammation-driven pathologies, while its antimicrobial properties inspire novel antibiotic strategies.
Structural studies of recombinant CTSG have elucidated its substrate specificity and activation process, which involves cleavage of a propeptide to generate the active enzyme. Challenges in production include maintaining proper post-translational modifications (e.g., glycosylation) for functional studies, necessitating optimized expression systems. Recent advances in protein engineering and crystallography have enhanced understanding of CTSG's interaction with inhibitors and substrates, supporting drug discovery efforts.
Overall, recombinant CTSG serves as a vital tool for dissecting neutrophil biology, inflammation, and host-pathogen interactions, with translational potential in diagnosing and treating immune-related disorders.
×
